Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
NCT05676489Phase 1Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2027
- Primary completion
- Aug 2029
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of [F-18]MeFAMP in glioma and brain metastasis (BM) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Human dosimetry at 4 hours and Safety of [F-18]MeFAMP. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
[F-18]MeFAMP
03
Conditions
gliomabrain metastasis (BM)
Beyond the preview
Go deeper on NCT05676489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676489.